Back to Directory
Last Updated: 03/06/2026

Redx Pharma

Manchester
Founded 2010
Small molecule drug discovery focused on fibrosis and oncology

Redx Pharma is a clinical-stage biotech developing novel small molecule therapeutics for fibrotic disease and cancer.

Its pipeline is anchored by zelasudil, a selective ROCK2 inhibitor in clinical development for idiopathic pulmonary fibrosis and other fibrotic indications, and zamaporvint, a Porcupine inhibitor targeting Wnt-ligand dependent tumours.

The company has a strong track record of out-licensing discovery assets, with programmes partnered with AstraZeneca, Jazz Pharmaceuticals and Loxo Oncology.

Company Notes